The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy.
DNA damage repair
DNA repair inhibitors
DNA topoisomerase II
EZH2
Myc
synthetic lethality
topoisomerase inhibitors
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
09 Jan 2023
09 Jan 2023
Historique:
received:
10
11
2022
revised:
31
12
2022
accepted:
06
01
2023
entrez:
21
1
2023
pubmed:
22
1
2023
medline:
22
1
2023
Statut:
epublish
Résumé
DNA topoisomerase II (Top2) is essential for all eukaryotic cells in the regulation of DNA topology through the generation of temporary double-strand breaks. Cancer cells acquire enhanced Top2 functions to cope with the stress generated by transcription and DNA replication during rapid cell division since cancer driver genes such as Myc and EZH2 hijack Top2 in order to realize their oncogenic transcriptomes for cell growth and tumor progression. Inhibitors of Top2 are therefore designed to target Top2 to trap it on DNA, subsequently causing protein-linked DNA breaks, a halt to the cell cycle, and ultimately cell death. Despite the effectiveness of these inhibitors, cancer cells can develop resistance to them, thereby limiting their therapeutic utility. To maximize the therapeutic potential of Top2 inhibitors, combination therapies to co-target Top2 with DNA damage repair (DDR) machinery and oncogenic pathways have been proposed to induce synthetic lethality for more thorough tumor suppression. In this review, we will discuss the mode of action of Top2 inhibitors and their potential applications in cancer treatments.
Identifiants
pubmed: 36678591
pii: ph16010094
doi: 10.3390/ph16010094
pmc: PMC9866718
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : CIHR
ID : PJT156150, PTJ178063, MOP-137007
Pays : Canada
Références
Expert Opin Ther Pat. 2021 May;31(5):435-452
pubmed: 33347360
Nucleic Acids Res. 2012 Jan;40(2):477-86
pubmed: 21937510
JAMA Oncol. 2021 Oct 01;7(10):1536-1543
pubmed: 34436521
Mol Cancer Ther. 2020 May;19(5):1091-1101
pubmed: 32220971
Biol Open. 2015 Oct 12;4(11):1436-47
pubmed: 26459242
Chromosoma. 2018 Jun;127(2):187-214
pubmed: 29327130
Prostate. 2008 Feb 15;68(3):255-63
pubmed: 18095286
J Cancer Res Clin Oncol. 2022 Jul;148(7):1813-1823
pubmed: 35633416
Cell Rep. 2022 May 17;39(7):110814
pubmed: 35584676
Eur J Med Chem. 2019 Jun 1;171:129-168
pubmed: 30917303
Mech Ageing Dev. 2008 Jul-Aug;129(7-8):391-407
pubmed: 18406444
Gene. 1998 Oct 23;221(2):255-66
pubmed: 9795238
Biomed Rep. 2020 Oct;13(4):21
pubmed: 32765860
Mol Cell. 2017 Jun 15;66(6):801-817
pubmed: 28622525
Chem Biol. 2011 Jun 24;18(6):743-51
pubmed: 21700210
Biochem Soc Trans. 2017 Jun 15;45(3):709-717
pubmed: 28620032
ACS Chem Biol. 2013 Jan 18;8(1):82-95
pubmed: 23259582
Nat Rev Drug Discov. 2020 Jan;19(1):23-38
pubmed: 31712683
Cancer Cell. 2016 Oct 10;30(4):563-577
pubmed: 27728805
PLoS One. 2015 Mar 16;10(3):e0119614
pubmed: 25774912
Cancer Res. 2022 May 3;82(9):1762-1773
pubmed: 35247890
Oncol Lett. 2014 Oct;8(4):1575-1580
pubmed: 25202370
J Biol Chem. 2017 Jul 14;292(28):11702-11713
pubmed: 28551686
Cancer Res. 2004 Feb 15;64(4):1215-9
pubmed: 14973119
Front Oncol. 2021 Feb 01;10:633142
pubmed: 33598437
Nat Rev Cancer. 2009 May;9(5):327-37
pubmed: 19377505
Clin Epigenetics. 2020 Sep 1;12(1):132
pubmed: 32873343
J Biol Chem. 2017 Jul 14;292(28):11951-11959
pubmed: 28546430
Int J Cancer. 2017 Apr 1;140(7):1551-1563
pubmed: 27997699
Curr Opin Genet Dev. 2013 Jun;23(3):271-9
pubmed: 23790415
Gen Pharmacol. 1999 Jan;32(1):155-8
pubmed: 9888268
Pharmaceuticals (Basel). 2010 Apr 28;3(5):1311-1334
pubmed: 27713304
EBioMedicine. 2017 Apr;18:83-93
pubmed: 28412251
Nat Commun. 2015 Dec 16;6:10191
pubmed: 26671524
Nat Commun. 2019 Jan 8;10(1):87
pubmed: 30622252
Mol Cell. 2012 Aug 24;47(4):497-510
pubmed: 22920291
Biochem J. 2018 Jan 23;475(2):373-398
pubmed: 29363591
Int J Clin Exp Pathol. 2015 Feb 01;8(2):1878-88
pubmed: 25973080
Mol Cancer Ther. 2018 Jun;17(6):1207-1216
pubmed: 29549168
J Hematol Oncol. 2018 Aug 1;11(1):99
pubmed: 30068368
Invest New Drugs. 1992 Nov;10(4):347-9
pubmed: 1487411
Nat Commun. 2013;4:2478
pubmed: 24072229
Nature. 2002 Oct 10;419(6907):624-9
pubmed: 12374981
Annu Rev Biophys Biomol Struct. 2004;33:95-118
pubmed: 15139806
Cancer Res. 2007 Aug 1;67(15):7078-81
pubmed: 17671173
Cancer Cell. 2010 Sep 14;18(3):244-57
pubmed: 20832752
Annu Rev Biochem. 2001;70:369-413
pubmed: 11395412
Prostate. 2007 Apr 1;67(5):547-56
pubmed: 17252556
DNA Repair (Amst). 2020 Jul - Aug;91-92:102869
pubmed: 32480356
J Biol Chem. 2015 Jan 9;290(2):851-60
pubmed: 25451918
Oncol Lett. 2021 Nov;22(5):810
pubmed: 34630717
Cancers (Basel). 2018 Dec 11;10(12):
pubmed: 30544963
Nature. 1996 Jan 18;379(6562):225-32
pubmed: 8538787
Methods Mol Biol. 2021;2153:87-99
pubmed: 32840774
Exp Hematol Oncol. 2021 Nov 3;10(1):51
pubmed: 34732266
Pharmacol Res. 2022 Apr;178:106162
pubmed: 35259479
Oncotarget. 2015 Aug 21;6(24):20474-84
pubmed: 26009876
Prz Menopauzalny. 2016 Dec;15(4):215-219
pubmed: 28250726
EMBO J. 2008 Jul 23;27(14):1953-62
pubmed: 18596698
Curr Med Chem. 2004 Sep;11(18):2443-66
pubmed: 15379707
Eur J Med Chem. 2018 Dec 5;160:108-119
pubmed: 30326371
Nat Commun. 2016 Dec 06;7:13785
pubmed: 27922005
Eur Rev Med Pharmacol Sci. 2019 Mar;23(5):2092-2102
pubmed: 30915754
Cancer Res. 2015 Oct 1;75(19):4176-87
pubmed: 26260527
Cancer Res. 2022 Feb 1;82(3):359-361
pubmed: 35110396
Sci Rep. 2022 Jul 1;12(1):11161
pubmed: 35778520
Nat Commun. 2018 Oct 4;9(1):4080
pubmed: 30287808
Nat Rev Mol Cell Biol. 2008 Apr;9(4):297-308
pubmed: 18285803
Breast Cancer Res Treat. 2013 Jun;139(2):301-10
pubmed: 23624778
Cancer Res. 2020 Dec 15;80(24):5449-5458
pubmed: 32978169
Cell Rep. 2018 Apr 03;23(1):239-254.e6
pubmed: 29617664
Trends Genet. 2008 Nov;24(11):529-38
pubmed: 18809224
Int J Mol Sci. 2021 Feb 22;22(4):
pubmed: 33671579
Biochim Biophys Acta. 1998 Oct 1;1400(1-3):139-54
pubmed: 9748545
Bioessays. 2014 Dec;36(12):1156-61
pubmed: 25171654
Sci Adv. 2022 Nov 25;8(47):eabm7069
pubmed: 36417527
Oncogene. 2021 Sep;40(39):5788-5798
pubmed: 34349243
Genes (Basel). 2019 Oct 30;10(11):
pubmed: 31671531
Nucleic Acids Res. 2021 Jun 4;49(10):5470-5492
pubmed: 33963870
Bioessays. 2021 Apr;43(4):e2000286
pubmed: 33480441
Curr Pharm Des. 2010 Jan;16(1):69-78
pubmed: 20214619
Cell. 2012 Mar 30;149(1):22-35
pubmed: 22464321
F1000Res. 2019 Sep 30;8:
pubmed: 31602296
Oncotarget. 2016 May 31;7(22):32172-83
pubmed: 27058754
J Cancer Res Clin Oncol. 2017 Mar;143(3):419-431
pubmed: 27838786
Leuk Res. 2008 Mar;32(3):491-4
pubmed: 17675230
FEBS J. 2020 Nov;287(22):4933-4951
pubmed: 32144855
Cancers (Basel). 2017 Jul 06;9(7):
pubmed: 28684677
J Biol Chem. 2018 Jul 6;293(27):10524-10535
pubmed: 29599286
Curr Oncol Rep. 2021 Jan 12;23(2):15
pubmed: 33433737
Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):1256-60
pubmed: 26787905
Mol Cell Biol. 1999 Jan;19(1):1-11
pubmed: 9858526
Am J Transl Res. 2019 Sep 15;11(9):5788-5799
pubmed: 31632548
Bioengineered. 2022 Feb;13(2):2207-2216
pubmed: 35012441
Clin Transl Radiat Oncol. 2020 Sep 22;25:61-66
pubmed: 33072895
Eur J Cancer. 2002 Feb;38(3):393-400
pubmed: 11818205
Biochim Biophys Acta Mol Basis Dis. 2018 Jan;1864(1):197-207
pubmed: 29045811
Mutat Res. 2020 May - Dec;821:111692
pubmed: 32172133
Transl Cancer Res. 2013 Jun;2(3):130-143
pubmed: 24000320
Biochim Biophys Acta. 2015 May;1849(5):525-43
pubmed: 24657798
Cancer Cell. 2016 Apr 11;29(4):536-547
pubmed: 27050099
Recent Results Cancer Res. 2018;211:217-233
pubmed: 30069770
Cold Spring Harb Perspect Biol. 2013 Sep 01;5(9):
pubmed: 24003211
Front Oncol. 2022 Mar 10;12:858756
pubmed: 35359409
Cancer Biol Ther. 2011 Nov 1;12(9):788-96
pubmed: 21892012
Front Genet. 2013 Jul 09;4:128
pubmed: 23847653
Medchemcomm. 2018 May 24;9(7):1142-1146
pubmed: 30109001
Front Genet. 2015 Apr 23;6:157
pubmed: 25954303
Nature. 2015 Apr 9;520(7546):239-42
pubmed: 25629630
Cancers (Basel). 2021 Jul 22;13(15):
pubmed: 34359577
Annu Rev Biochem. 1989;58:351-75
pubmed: 2549853
Pharmacol Ther. 2003 Aug;99(2):167-81
pubmed: 12888111
Br J Cancer. 2018 Aug;119(3):347-356
pubmed: 29988112
J Biol Chem. 2008 May 23;283(21):14883-92
pubmed: 18337252
Mol Cancer. 2019 Jan 18;18(1):11
pubmed: 30657058
Mol Cell. 2022 Jan 6;82(1):140-158.e12
pubmed: 34890565
Cancer Res. 2022 Feb 1;82(3):458-471
pubmed: 34903608
World J Gastroenterol. 2013 Oct 28;19(40):6894-901
pubmed: 24187467
Science. 2006 Jun 23;312(5781):1798-802
pubmed: 16794079
Genes Dev. 2010 Jun 15;24(12):1236-41
pubmed: 20551172
Cancer Res. 2007 Sep 15;67(18):8839-46
pubmed: 17875725
Sci Rep. 2018 Oct 19;8(1):15477
pubmed: 30341375
Cancer Sci. 2021 Nov;112(11):4604-4616
pubmed: 34449935
Proc Natl Acad Sci U S A. 2018 Nov 6;115(45):E10642-E10651
pubmed: 30352856
Mol Cancer. 2020 Apr 27;19(1):79
pubmed: 32340605
Gastroenterology. 2007 Nov;133(5):1569-78
pubmed: 17983804
Eur J Cancer. 2021 Jul;152:68-77
pubmed: 34087573
Cancer Discov. 2014 Oct;4(10):1126-39
pubmed: 25168287
Nat Rev Mol Cell Biol. 2016 Nov;17(11):703-721
pubmed: 27649880
Clin Cancer Res. 2017 Nov 15;23(22):7072-7083
pubmed: 28899973
Lancet Oncol. 2020 Nov;21(11):1433-1442
pubmed: 33035457
Nat Rev Mol Cell Biol. 2019 Nov;20(11):698-714
pubmed: 31263220
Nucleic Acids Res. 2018 Apr 20;46(7):3446-3457
pubmed: 29447383
Int J Mol Sci. 2022 Sep 10;23(18):
pubmed: 36142413
Nat Genet. 2010 Aug;42(8):668-75
pubmed: 20601956